(2E)-3-(dimethylamino)-1-[6-(propyloxy)pyrazolo[1,5-b]pyridazin-3-yl]-2-propen-1-one | 748141-91-5

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (2E)-3-(dimethylamino)-1-[6-(propyloxy)pyrazolo[1,5-b]pyridazin-3-yl]-2-propen-1-one
• 英文别名: (E)-3-(dimethylamino)-1-(6-propoxypyrazolo[1,5-b]pyridazin-3-yl)prop-2-en-1-one
• CAS: 748141-91-5
• 化学式: C₁₄H₁₈N₄O₂
• 分子量: 274.323
• InChiKey: QKGOVWXNMDJOEX-BQYQJAHWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  20
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  59.7
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  N-(3-trifluoromethylphenyl)guanidine nitrate 、 (2E)-3-(dimethylamino)-1-[6-(propyloxy)pyrazolo[1,5-b]pyridazin-3-yl]-2-propen-1-one 在 potassium carbonate 作用下， 以 乙二醇甲醚 为溶剂， 生成 Pyrazolo[1,5-b]pyridazine deriv. 41
  参考文献：
  名称：

  N-Phenyl-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amines as Potent and Selective Inhibitors of Glycogen Synthase Kinase 3 with Good Cellular Efficacy

  摘要：

  Glycogen synthase kinase 3 regulates glycogen synthase, the rate-determining enzyme for glycogen synthesis. Liver and muscle glycogen synthesis is defective in type 2 diabetics, resulting in elevated plasma glucose levels. Inhibition of GSK-3 could potentially be an effective method to control plasma glucose levels in type 2 diabetics. Structure-activity studies on a N-phenyl-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amine series have led to the identification of potent and selective compounds with good cellular efficacy. Molecular modeling studies have given insights into the mode of binding of these inhibitors. Since the initial leads were also potent inhibitors of CDK-2/CDK-4, an extensive SAR was performed at various positions of the pyrazolo[1,5-b]pyridazin core to afford potent GSK-3 inhibitors that were highly selective over CDK-2. In addition, these inhibitors also exhibited very good cell efficacy and functional response. A representative example was shown to have good oral exposure levels, extending their utility in an in vivo setting. These inhibitors provide a viable lead series in the discovery of new therapies for the treatment of type 2 diabetes.

  DOI：

  10.1021/jm040063i
• 作为产物：
  描述：

  3-氯-6-丙基氧基哒嗪 在 palladium on activated charcoal 氢气 、 potassium hydrogencarbonate 、 hydroxylamine-O-sulfonic acid 作用下， 以 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 20.0~90.0 ℃ 、344.74 kPa 条件下， 生成 (2E)-3-(dimethylamino)-1-[6-(propyloxy)pyrazolo[1,5-b]pyridazin-3-yl]-2-propen-1-one
  参考文献：
  名称：

  N-Phenyl-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amines as Potent and Selective Inhibitors of Glycogen Synthase Kinase 3 with Good Cellular Efficacy

  摘要：

  Glycogen synthase kinase 3 regulates glycogen synthase, the rate-determining enzyme for glycogen synthesis. Liver and muscle glycogen synthesis is defective in type 2 diabetics, resulting in elevated plasma glucose levels. Inhibition of GSK-3 could potentially be an effective method to control plasma glucose levels in type 2 diabetics. Structure-activity studies on a N-phenyl-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amine series have led to the identification of potent and selective compounds with good cellular efficacy. Molecular modeling studies have given insights into the mode of binding of these inhibitors. Since the initial leads were also potent inhibitors of CDK-2/CDK-4, an extensive SAR was performed at various positions of the pyrazolo[1,5-b]pyridazin core to afford potent GSK-3 inhibitors that were highly selective over CDK-2. In addition, these inhibitors also exhibited very good cell efficacy and functional response. A representative example was shown to have good oral exposure levels, extending their utility in an in vivo setting. These inhibitors provide a viable lead series in the discovery of new therapies for the treatment of type 2 diabetes.

  DOI：

  10.1021/jm040063i

文献信息

• <i>N</i>-Phenyl-4-pyrazolo[1,5-<i>b</i>]pyridazin-3-ylpyrimidin-2-amines as Potent and Selective Inhibitors of Glycogen Synthase Kinase 3 with Good Cellular Efficacy
  作者：Francis X. Tavares、Joyce A. Boucheron、Scott H. Dickerson、Robert J. Griffin、Frank Preugschat、Stephen A. Thomson、Tony Y. Wang、Hui-Qiang Zhou

  DOI：10.1021/jm040063i

  日期：2004.9.1

  Glycogen synthase kinase 3 regulates glycogen synthase, the rate-determining enzyme for glycogen synthesis. Liver and muscle glycogen synthesis is defective in type 2 diabetics, resulting in elevated plasma glucose levels. Inhibition of GSK-3 could potentially be an effective method to control plasma glucose levels in type 2 diabetics. Structure-activity studies on a N-phenyl-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amine series have led to the identification of potent and selective compounds with good cellular efficacy. Molecular modeling studies have given insights into the mode of binding of these inhibitors. Since the initial leads were also potent inhibitors of CDK-2/CDK-4, an extensive SAR was performed at various positions of the pyrazolo[1,5-b]pyridazin core to afford potent GSK-3 inhibitors that were highly selective over CDK-2. In addition, these inhibitors also exhibited very good cell efficacy and functional response. A representative example was shown to have good oral exposure levels, extending their utility in an in vivo setting. These inhibitors provide a viable lead series in the discovery of new therapies for the treatment of type 2 diabetes.